PLP (139-151) is an encephalitogenic peptide fragment of myelin proteolipid protein (PLP).1 In vivo, PLP (139-151) (150 µg/animal) induces the formation of inflammatory foci, axonal injury, and demyelination in the spinal cord, as well as motor deficits in mice. It is commonly used to induce experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS), in mice.1,2,3
1.Lourbopoulos, A., Matsoukas, M.-T., Katsara, M., et al.Cyclization of PLP139-151 peptide reduces its encephalitogenic potential in experimental autoimmune encephalomyelitisBioorg. Med. Chem.26(9)2221-2228(2018) 2.Reddy, J., Bettelli, E., Nicholson, L., et al.Detection of autoreactive myelin proteolipid protein 139-151-specific T cells by using MHC II (IAs) tetramersJ. Immunol.170(2)870-877(2003) 3.Mohindru, M., Kang, B., and Kim, B.S.Functional maturation of proteolipid protein139-151-specific Th1 cells in the central nervous system in experimental autoimmune encephalomyelitisJ. Neuroimmunol.155(1-2)127-135(2004)